At a glance
ClinicalIndex Comparison RecordPhase 2Active· 10 enrolled
Drug / intervention
Trametinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating Bone Marrow Aspiration and Biopsy and Trametinib for Juvenile Myelomonocytic Leukemia and Neurofibromatosis Type 1. Active but no longer recruiting, targeting 10 participants across 57 sites.
Detailed Summary
This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsChildren's Oncology Group
Timeline
Phase 2Active
2018201920202021202220232024202520262027
First PostedJun 2017
Enrollment StartSep 2018
Primary CompletionMar 2023
TodayJul 2026
Study CompletionOct 2026
First PostedJun 19, 2017
Enrollment StartSep 9, 2018
Primary CompletionMar 31, 2023
Study CompletionOct 3, 2026
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 9.0 years ago
Interventions
Bone Marrow Aspiration and Biopsyprocedure
Undergo bone marrow aspiration or biopsy
Trametinibdrug
Given PO